文献速递核素与放射性配体治疗肿瘤 PET/CT

SPECT达到PET的速度:基于CZT的全身体SPECT/CT在177Lu-DOTATATE和177Lu-PSMA617治疗后成像中的可行性研究

SPECT at the speed of PET: a feasibility study of CZT-based whole-body SPECT/CT in the post 177Lu-DOTATATE and 177Lu-PSMA617 setting.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-03-04

该研究评估了新型多探测器碲锌镉(CZT)基SPECT/CT(StarGuide)在177Lu标记放射性药物治疗后全身成像中的可行性。31例接受177Lu-DOTATATE(n=17)或177Lu-PSMA617(n=14)治疗的患者进行了StarGuide治疗后扫描,部分也使用标准GE Discovery 670 Pro SPECT/CT扫描。初步评估显示,StarGuide快速扫描的检测/靶向率与标准SPECT/CT相当,并能检测出治疗前PET上符合RECIST标准的大病灶。

要点

  • StarGuide全身SPECT/CT从头顶至大腿中段采集,4个床位,每床位3分钟,总扫描时间12分钟。
  • 标准GE Discovery 670 Pro SPECT/CT通常采集2个床位覆盖胸腹盆,总扫描时间32分钟。
  • StarGuide快速治疗后扫描的检测/靶向率与Discovery 670 Pro SPECT/CT相当。

核心结论

  • 使用新型StarGuide系统进行快速全身治疗后SPECT/CT采集是可行的。
  • 短扫描时间改善患者临床体验和依从性,可能促进治疗后SPECT的更多采用。
  • 这为向接受靶向放射性核素治疗的患者提供基于影像的治疗反应评估和个性化剂量学提供了可能。

研究设计与样本

  • 回顾性分析,纳入31例(34-89岁;均值±标准差,65.5±12.1)接受177Lu-DOTATATE(n=17)或177Lu-PSMA617(n=14)标准治疗的患者。
  • 治疗后使用StarGuide扫描,部分患者也使用标准GE Discovery 670 Pro SPECT/CT扫描。
  • 所有患者在首次治疗周期前均接受64Cu-DOTATATE或18F-DCFPyL PET/CT用于 eligibility 检查。

主要发现

  • 从2021年11月至2022年8月,共识别出50次使用新成像方案的治疗后扫描。
  • StarGuide系统采集从头顶至大腿中段的治疗后SPECT/CT扫描,4个床位,每床位3分钟,总扫描时间12分钟。
  • 标准GE Discovery 670 Pro SPECT/CT系统通常采集2个床位覆盖胸、腹、盆,总扫描时间32分钟。
  • 治疗前64Cu-DOTATATE PET在GE Discovery MI PET/CT上采集20分钟,4个床位;18F-DCFPyL PET采集8-10分钟,4-5个床位。
  • 初步评估显示,StarGuide系统快速治疗后扫描的检测/靶向率与Discovery 670 Pro SPECT/CT系统相当,并能检测出治疗前PET上符合RECIST标准的大病灶。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the feasibility of using the StarGuide (General Electric Healthcare, Haifa, Israel), a new generation multi-detector cadmium-zinc-telluride (CZT)-based SPECT/CT, for whole-body imaging in the setting of post-therapy imaging of 177Lu-labeled radiopharmaceuticals. METHODS: Thirty-one patients (34-89 years old; mean ± SD, 65.5 ± 12.1) who were treated with either 177Lu-DOTATATE (n=17) or 177Lu-PSMA617 (n=14) as part of standard of care were scanned post-therapy with the StarGuide; some were also scanned with the standard GE Discovery 670 Pro SPECT/CT. All patients had either 64Cu-DOTATATE or 18F-DCFPyL PET/CT prior to first cycle of therapy for eligibility check. The detection/targeting rate (lesion uptake greater than blood pool uptake) of large lesions meeting RECIST 1.1 size criteria on post-therapy StarGuide SPECT/CT was evaluated and compared to the standard design GE Discovery 670 Pro SPECT/CT (when available) and pre-therapy PET by two nuclear medicine physicians with consensus read. RESULTS: This retrospective analysis identified a total of 50 post-therapy scans performed with the new imaging protocol from November 2021 to August 2022. The StarGuide system acquired vertex to mid-thighs post-therapy SPECT/CT scans with 4 bed positions, 3 min/bed and a total scan time of 12 min. In comparison, the standard GE Discovery 670 Pro SPECT/CT system typically acquires images in 2 bed positions covering the chest, abdomen, and pelvis with a total scan time of 32 min. The pre-therapy 64Cu-DOTATATE PET takes 20 min with 4 bed positions on GE Discovery MI PET/CT, and 18F-DCFPyL PET takes 8-10 min with 4-5 bed positions on GE Discovery MI PET/CT. This preliminary evaluation showed that the post-therapy scans acquired with faster scanning time using StarGuide system had comparable detection/targeting rate compared to the Discovery 670 Pro SPECT/CT system and detected large lesions defined by RECIST criteria on the pre-therapy PET scans. CONCLUSION: Fast acquisition of whole-body post-therapy SPECT/CT is feasible with the new StarGuide system. Short scanning time improves the patients' clinical experience and compliance which may lead to increased adoption of post-therapy SPECT. This opens the possibility to offer imaged-based treatment response assessment and personalized dosimetry to patients referred for targeted radionuclide therapies.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Song H, Ferri V, Duan H, et al. SPECT at the speed of PET: a feasibility study of CZT-based whole-body SPECT/CT in the post 177Lu-DOTATATE and 177Lu-PSMA617 setting. Eur J Nucl Med Mol Imaging. 2023. PMID: 36869177. doi:10.1007/s00259-023-06176-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。